Skip to main content
Fadi Braiteh, MD, Oncology, Las Vegas, NV

FadiSBraitehMD

Oncology Las Vegas, NV

Physician

Dr. Braiteh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Braiteh's full profile

Already have an account?

  • Office

    3730 S Eastern Ave
    Las Vegas, NV 89169
    Phone+1 702-952-3400
    Fax+1 702-952-3461

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2000 - 2003
  • St Joseph's University Medical School
    St Joseph's University Medical SchoolClass of 1998

Certifications & Licensure

  • OH State Medical License
    OH State Medical License Current
  • NV State Medical License
    NV State Medical License 2010 - 2025
  • TX State Medical License
    TX State Medical License 2004 - 2025
  • MI State Medical License
    MI State Medical License 2009 - 2013
  • CT State Medical License
    CT State Medical License 2003 - 2004

Awards, Honors, & Recognition

  • Vegas Seven Castle Connolly, 2014
  • Desert Companion Castle Connolly, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Oxford University Press Has Registered This DOI Pre-Publication  
    Fadi Braiteh, MD, Oxford University Press

Press Mentions

  • Nab-Paclitaxel plus Gemcitabine Opens up Treatment Options in Pancreatic Cancer
    Nab-Paclitaxel plus Gemcitabine Opens up Treatment Options in Pancreatic CancerMarch 16th, 2016
  • Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC
    Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBCMarch 12th, 2016
  • US Oncology Research Translational Oncology Program Enrolls 2,000
    US Oncology Research Translational Oncology Program Enrolls 2,000February 4th, 2016
  • Join now to see all

Professional Memberships